Polar Asset Management Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Polar Asset Management Partners’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,104	Closed	-$1.87M	–	672
2025 Q3	$1.87M	Sell	4,104 -5,496	-57%	-$2.24M	0.02%	397
2025 Q2	$3.13M	Buy	+9,600	New	+$2.66M	0.05%	261
2024 Q4	–	Sell	-5,900	Closed	-$1.62M	–	670
2024 Q3	$1.62M	Sell	5,900 -4,100	-41%	-$1.07M	0.03%	361
2024 Q2	$2.43M	Sell	10,000 -12,600	-56%	-$1.99M	0.05%	293
2024 Q1	$3.38M	Buy	+22,600	New	+$3.77M	0.06%	277
2022 Q4	–	Sell	-19,600	Closed	-$3.92M	–	1238
2022 Q3	$3.92M	Buy	+19,600	New	+$3.74M	0.05%	564

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Polar Asset Management Partners's ALNY Position: Q4 2025 in Review

Polar Asset Management Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 4,104 shares — an estimated $1.87M sold.

Polar Asset Management Partners first reported a position in ALNY in Q3 2022 and held it in 6 quarters. The position peaked at $3.92M in Q3 2022. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

Polar Asset Management Partners reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Polar Asset Management Partners sold 4,104 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $1.87M.
Polar Asset Management Partners first reported a position in Alnylam Pharmaceuticals in Q3 2022 and held it in 6 quarters.
Polar Asset Management Partners's Alnylam Pharmaceuticals position peaked at $3.92M in Q3 2022.
851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Polar Asset Management Partners's 13F filing for Q4 2025, filed 17 Feb 2026.